<< Read Full Article
<< Read Full Article
Regulatory news and analyst actions nudged a few biotech stocks up ahead of the weekend, maintaining a four-day rebound for health indices.
After Thursday's close, a Food and Drug Administration panel recommended approval for Abbott's(ABT Quote) drug eluting stent, the Xience V, a mesh, antibiotic-coated tube used to prop open clogged arteries. The stent was launched in Europe and international markets in 2006. The panel recommended that the agency approve it in the U.S. with conditions related to post-marketing study requirements among other things, according to the company.
Abbot shares were trading up 51 cents, or 0.9%, at $57.51. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet